Hype, Promise, and Reality Orthopedic Use of Biologics (2021 Annual Meeting)-Hype, Promise, and Reality: Orthopedic Use of Biologics in 2021'-McIntyre

Hype, Promise, and Reality: Orthopedic Use of Biologics in 2021'-McIntyre

Video Transcription

Video Summary

In this video, the speaker discusses the potential use of orthobiologics such as hyaluronic acid, long-acting steroids, platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and adipose tissue for treating patients with orthopedic conditions. The speaker highlights the size of the market for orthobiologics, estimating it to be around $4.5 billion per year, with projected growth at a compound annual growth rate of 15%. They emphasize the need for non-operative alternatives to total joint replacement and the unmet need in the market. The speaker also discusses the operational side of incorporating orthobiologics into a medical practice, including billing and reimbursement considerations. They advise consulting with carriers to understand coverage rules and suggest using advanced beneficiary notifications for non-covered and experimental treatments. The speaker provides coding information for various orthobiologics and stresses the importance of staying informed on the changing regulations and collecting outcome data for justification and marketing purposes. The speaker concludes by expressing the potential of using cell therapy and advises establishing a separate business entity or service line for orthobiologics.

Asset Caption

Dr. Louis F. McIntyre

Keywords

orthobiologics

hyaluronic acid

platelet-rich plasma

BMAC

cell therapy